Korsana Biosciences, Inc. (KRSA)
31.31
-2.12
(-6.34%)
USD |
NASDAQ |
Oct 23, 16:00
31.44
+0.14
(+0.43%)
After-Hours: 20:00
Korsana Biosciences Enterprise Value : 17.65M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 17.65M |
| October 22, 2026 | 18.93M |
| October 21, 2026 | 18.39M |
| October 20, 2026 | 17.48M |
| October 19, 2026 | 17.71M |
| October 16, 2026 | 18.30M |
| October 15, 2026 | 19.07M |
| October 14, 2026 | 19.48M |
| October 13, 2026 | 17.86M |
| October 12, 2026 | 19.31M |
| October 09, 2026 | 19.23M |
| October 08, 2026 | 18.98M |
| October 07, 2026 | 17.85M |
| October 06, 2026 | 17.93M |
| October 05, 2026 | 17.29M |
| October 02, 2026 | 17.15M |
| October 01, 2026 | 17.58M |
| September 30, 2026 | 18.06M |
| September 29, 2026 | 19.28M |
| September 28, 2026 | 17.35M |
| September 25, 2026 | 17.46M |
| September 24, 2026 | 21.22M |
| September 23, 2026 | 18.25M |
| September 22, 2026 | 19.88M |
| September 21, 2026 | 18.80M |
| Date | Value |
|---|---|
| September 18, 2026 | 19.88M |
| September 17, 2026 | 19.11M |
| September 16, 2026 | 17.60M |
| September 15, 2026 | 18.11M |
| September 14, 2026 | 17.83M |
| September 11, 2026 | 18.01M |
| September 10, 2026 | 13.54M |
| September 09, 2026 | 14.54M |
| September 08, 2026 | 12.91M |
| September 04, 2026 | 16.70M |
| September 03, 2026 | 19.72M |
| September 02, 2026 | 17.85M |
| September 01, 2026 | 16.36M |
| August 31, 2026 | 14.27M |
| August 28, 2026 | 14.74M |
| August 27, 2026 | 15.59M |
| August 26, 2026 | 16.27M |
| August 25, 2026 | 15.63M |
| August 24, 2026 | 15.34M |
| August 21, 2026 | 15.16M |
| August 20, 2026 | 15.93M |
| August 19, 2026 | 16.19M |
| August 18, 2026 | 16.14M |
| August 17, 2026 | 15.76M |
| August 14, 2026 | 14.74M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Climb Bio, Inc. | 403.47M |
| Q32 Bio, Inc. | 104.35M |
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.755M |
| Total Expenses (Quarterly) | 1.755M |
| EPS Diluted (Quarterly) | -2.890 |
| Earnings Yield | -37.56% |
| Normalized Earnings Yield | -37.56 |